India Globalization Capital Inc (IGC) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $0.27 (+2.03%), Market cap $0.03B, 52-week low–high $0.25 ~ $0.47.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was
Financial statements, price targets, institutional (13F) holdings and related news for India Globalization Capital Inc are updated in real time on BlackAll Trade.
India Globalization Capital Inc trades at $0.27 (+2.03%). Real-time quotes and charts are available on BlackAll Trade.
India Globalization Capital Inc has a market cap of about $0.03B.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in th